Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could mangosteen help control type 2 diabetes?

NCT ID NCT07172269

Disease control Sponsor: Mais Qais Hbeeb Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested whether adding a mangosteen supplement to standard diabetes drugs (sitagliptin/metformin) improves blood sugar control in 47 adults with type 2 diabetes. Participants took either the standard drugs alone or with mangosteen for 12 weeks. Researchers measured changes in HbA1c, insulin resistance, and inflammation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
mangosteen supplement (Garcinia mangostana extract)
What this could lead to
If it works, this could point toward a natural supplement to help manage blood sugar and reduce inflammation in type 2 diabetes.
What could go wrong
This is a small, early-stage trial with only 47 patients. Results may not apply to everyone, and supplements are not a replacement for standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

58 people

The number who actually took part.

Started

Sep 2024

Finished

May 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged ≥30 years. * Diagnosed with Type 2 Diabetes Mellitus according to American Association of Clinical Endocrinologists (AACE) criteria. * HbA1c between 7.5% and 9%. Exclusion Criteria: * T1DM patients were excluded from study. * T2DM patients receiving any anti-diabetic treatment other than the study intervention or T2DM patients receiving insulin therapy. * Patients with T2DM complications or having liver disease, kidney disease. * Patients with other metabolic diseases (thyroid disorders, adrenal disorders, growth hormone disorders and pituitary disorders) that may affect glycemic and metabolic status. * Patients receiving drugs (steroids, contraceptives, anticoagulants and thyroid medications) or using other nutritional supplements or herbal remedies that may interfere with lab results. * Pregnant or lactating women.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabete mellitus are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetes mellitus Inflammation Insulin Resistance type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabete mellitus Dyslipidemia in patients with diabetes mellitus Insulin resistance Obesity type 2 diabetes mellitus Type 2 diabetes

Contacts and locations

Locations

  • National Diabetes Center for Treatment and Research

    Baghdad, Iraq

More trials for these conditions

Other studies related to the condition(s) this trial covers.